COMMUNIQUÉS West-GlobeNewswire

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
12/02/2026
Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul [...]
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
12/02/2026
FY 2025 sales growth of 10.9% at CER 1 , or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1% 1 ), Rare Disease (102.5% 1 ) and Neuroscience (9.7% 1 ); Somatuline® sales growth of 4.3% [...]
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
12/02/2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness. 2026 guidance reflects continued growth in Travel Health (10% from own [...]
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
12/02/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the [...]
Nicox confirme son éligibilité au PEA-PME
12/02/2026
Communiqué de presse Nicox confirme son éligibilité au PEA-PME 12 février 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société [...]
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi
12/02/2026
Belén Garijo nommée Directrice générale de Sanofi Paris, le 12 février 2026. Le Conseil d’administration de Sanofi s’est réuni le 11 février 2026 et a décidé de ne pas renouveler le mandat d’administrateur de Paul [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
12/02/2026
Oslo, Norway, 12 th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin [...]
Xilio Therapeutics Announces Pricing of Underwritten Offering
12/02/2026
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
BioRestorative Announces Pricing of $5.0 Million Public Offering
12/02/2026
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell- [...]
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
11/02/2026
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 [...]
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
12/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/02/2026
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
11/02/2026
ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report [...]
Biogen Announces Board Chair Transition
11/02/2026
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced [...]
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
11/02/2026
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Etienna Bio, Inc. Announces Formation of Scientific Advisory Board with Renowned UMass Chan Leaders
11/02/2026
Silvia Corvera, MD, and Michael Czech, PhD, Join SAB to Advance Autologous Regenerative Cell Platform LEAWOOD, Kan., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a regenerative biotechnology company developing [...]
Java Burn Drops Product Information Updated as Consumer Interest in Liquid Coffee Supplement Options for Weight Management Grows in 2026
11/02/2026
An informational overview examining liquid coffee supplement category context, publicly available Java Burn Drops product disclosures, and what consumers often consider when researching coffee-based weight management [...]
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
11/02/2026
Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon ® CNP under FDA Priority Review [...]

Pages